Features of the anti-erythrocyte antibodies screening results interpretation in patients with hematological diseases
- Authors: Krobinets I.I1, Mineeva N.V1, Bodrova N..1, Sisoeva E.A1, Gavrovskaya S.V.1, Sidorkevich S.V1, Bessmeltsev S.S1
-
Affiliations:
- Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
- Issue: Vol 103, No 1 (2022)
- Pages: 14-22
- Section: Theoretical and clinical medicine
- Submitted: 21.12.2021
- Accepted: 26.01.2022
- Published: 07.02.2022
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/90782
- DOI: https://doi.org/10.17816/KMJ2022-14
- ID: 90782
Cite item
Abstract
Background. Screening for anti-erythrocyte alloantibodies is a mandatory pre-transfusion test. The correct interpretation of the screening results plays a key role in ensuring the immunological safety of hemotransfusion therapy.
Aim. To study the features of anti-erythrocyte antibodies detection in patients with hematological diseases.
Material and methods. The study was performed with blood samples of 1269 patients with hematological diseases (569 male and 700 female patients aged 18–85 with a median of 63 years). Screening and identification were carried out in indirect antiglobulin test using ID Coombs Anti-IgG gel cards with 4 and 15 samples of test erythrocytes as well as the salt agglutination method. The results were evaluated visually. The Pearson chi-squared test was used to check the statistical significance of differences in the alloimmune anti-erythrocyte antibodies frequency detection. The differences were considered statistically significant at p ≤0.05.
Results. Interpretation of the anti-erythrocyte alloantibodies screening results was difficult in 6.55% of cases and was associated with the presence of autoantibodies in plasma (0.6%) and cross-reactive antibodies (5.9%). Аnti-erythrocyte alloantibodies were detected in 2.05% of cases which required further identification of antibody specificity. Antibodies to Rh system antigens were detected in 68.2% of cases, to antigens of other erythrocyte systems — in 31.8% of cases. In Rh-negative patients only anti-D or anti-DC antibodies were detected. Rh-positive patients were more likely to have anti-K antibodies (30%). Anti-E antibodies were discovered in 20% of cases, anti-Cw and anti-Fya — in 10% each. Alloantibodies were detected most frequently in patients with β-thalassemia (20%), aplastic anemia (13%), hemophilia (9.2%) and thrombophilia (6.9%) and less frequently in patients with hemoblastosis and hematopoiesis depression (0.3–2.4%). Cross-reacting antibodies were detected more frequently in patients with multiple myeloma (74.7%; p ≤0.05) than in patients with chronic lymphocytic leukemia (17.3%), myelodysplastic syndrome (5.3%), and acute leukemia (2.7%).
Conclusion. The reasons for the difficulties in interpreting the alloantibody screening results in hematological patients were the presence of autoantibodies (0.6%), alloantibodies (2.05%) and cross-reacting antibodies (5.9%).
Full Text
About the authors
Irina I Krobinets
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Author for correspondence.
Email: transfusion_spb@mail.ru
ORCID iD: 0000-0002-6404-2387
Cand. Sci. (Biol.), Senior Researcher, laboratory of immunohematology, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaNatalya V Mineeva
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Email: izoserologia@mail.ru
ORCID iD: 0000-0001-7137-8877
D.Sci. (Biol.), Prof., Manager, laboratory of immunohematology, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaNatalya N Bodrova
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Email: izoserologia@mail.ru
Senior Researcher, laboratory of immunohematology, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaElena A Sisoeva
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Email: izoserologia@mail.ru
Senior Researcher, laboratory of immunohematology, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaSvetlana V. Gavrovskaya
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Email: izoserologia@mail.ru
Senior Researcher, laboratory of immunohematology, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaSergey V Sidorkevich
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Email: bloodscience@mail.ru
ORCID iD: 0000-0001-9931-9406
D.Sci. (Med.), Director, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaStanislav S Bessmeltsev
Russian Scientific Research Institute of Hematology and Transfusiology of the Federal biomedical agency
Email: bessmeltsev@yandex.ru
ORCID iD: 0000-0001-7280-7100
Prof., Deputy Director, Russian Research Institute of Hematology and Transfusiology
Russian Federation, St. Petersburg, RussiaReferences
- Bessmeltsev SS, Romanenko NA. Anemiya pri opukholevykh zabolevaniyakh sistemy krovi. Rukovodstvo dlya vrachey. (Anemia in tumor diseases of the blood system. Hands. for doctors.) Moscow: SIMK; 2017. 228 p. (In Russ.)
- Mineeva NV, Pashkova IA, Krobinets II, Sysoeva EA. Allosensibilisation to erythrocyte antigens. Onkogematologia. 2015;10(4):60–65. (In Russ.) doi: 10.17650/1818-8346-2015-10-4-60-65.
- Rakhmani AF, Mikhaylova EA, Dubinkin IV. Refractoriness to donor platelets transfusion in patients with aplastic anemia and hemoblastosis. Onkogematologia. 2018;13(2):62–72. (In Russ.) doi: 10.17650/1818-8346-2018-13-2-62-72.
- Krobinets II, Mineeva NV, Bogdanova IO, Chechetkin AV. Human neutrophil antigen allele frequencies and assessment of HNA alloimmunisation risk in donors and hematological patients. Bulletin of Siberian Medicine. 2020;19(2):48–54. (In Russ.) doi: 10.20538/1682-0363-2020-2-48-54.
- Westhoff CM, Reid ME. Review: the Kell, Duffy, and Kidd blood group systems. Immunohematology. 2004;20:37–49. doi: 10.21307/immunohematology-2019-420.
- Butina EV, Mineeva NV, Zaitseva GA, Poponina EA, Yovdiy AV. Red blood cell alloimmunization in patients with hematology/oncology disorders. Transfusion. 2019;(2):27–34. (In Russ.)
- Leisch M, Weiss L, Lindlbauer N, Jungbauerd C, Egle A, Rohde E, Greil R, Grabmer C, Pleyer L. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine — A retrospective single center experience. Leuk Res. 2017;59:12–19. doi: 10.1016/j.leukres.2017.05.006.
- Gottvall T, Filbey D. Alloimmunization in pregnancy during the years 1992–2005 in the central west region of Sweden. Acta Obstet Gynecol Scand. 2008;87:843–848. doi: 10.1080/00016340802268880.
- Flegel WA. Molecular genetics and clinical applications for RH. Transfus Apher Sci. 2011;44:81–91. doi: 10.1016/j.transci.2010.12.013.
- Zalpuri S, Middelburg RA, Schonewille H, de Vooght KMK, le Cessie S, van der Bom JG, Zwaginga JJ. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion. 2014;54:278–284. doi: 10.1111/trf.12312.
- Zalpuri S, Evers D, Zwaginga JJ, Schonewille H, de Vooght KM, le Cessie S, van der Bom JG. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion. 2014;54:1981–1987. doi: 10.1111/trf.12639.
- Stiegler G, Sperr W, Lorber C, Fabrizii V, Hocker P, Panzer S. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol. 2001;80:330–333. doi: 10.1007/s002770100308.
- Senkina EA, Zaitseva GA, Zagoskina TP, Gradoboeva TG. Immune disturbances in patients with multiple myeloma. Medical immunology (Russia). 2009;11(6):571–576. (In Russ.) doi: 10.15789/1563-0625-2009-6-571-576.
- Chubukina ZhV, Bubnova LN, Bessmeltsev SS. Glazanova GV, Rozanova OE, Pavlova IE. Nonspecific protective factors and humoral immunity in patients with multiple myeloma. Meditsina ekstremalnykh situatsiy. 2012;(2):93–98. (In Russ.)